Novartis suffers another setback in research – the share price plummets by over 10 percent

Novartis suffers setback: A drug for muscle disease flops in Phase III, causing the share price to plummet by over 10%. This raises questions about the pharmaceutical company's research strategy and its most expensive acquisition.